Overview

Kidney Damage in Patients With Normal eGFR

Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
This is a pilot study, randomized, double-blind, parallel group comparison of two iodinated contrast agents used during percutaneous coronary intervention (PCI). All patients enrolled must have normal eGFR. Statistical summaries will be presented to analyse the various laboratory tests for the two groups.
Phase:
Phase 4
Details
Lead Sponsor:
Bracco Diagnostics, Inc